Karim Chamie, MD
Urology · Los Angeles, CANPI 1962478420
Payments from drug & device makers
Across 346 payments — averaging $12,494 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.7M
- Astellas US Technologies$1M
- Urogen Pharma, Inc.$299K
- Pfizer$100K
- Johnson & Johnson$70K
- AstraZeneca$56K
- plus $110K from 21 others
Across 4 payments — averaging $11,753 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$45K
- F. Hoffmann-la Roche AG$1K
- Urogen Pharma, Inc.$352
What the payments were for
- Consulting fees$169,64058%
- Speaking & faculty fees$87,80630%
- Travel & lodging$23,5648%
- Food & beverage$9,7733%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 87 | $2,651,690 |
| Astellas US Technologies | 8 | $1,036,521 |
| Urogen Pharma, Inc. | 50 | $298,955 |
| Pfizer | 17 | $99,860 |
| Johnson & Johnson | 63 | $69,885 |
| AstraZeneca | 11 | $56,148 |
| Astellas Pharma Global Development | 5 | $50,794 |
| E.r. Squibb & Sons, L.L.C. | 10 | $17,983 |
| Janssen Scientific Affairs, LLC | 5 | $13,434 |
| Photocure Inc | 6 | $8,933 |
| Astellas Pharma US Inc | 12 | $6,223 |
| F. Hoffmann-la Roche AG | 2 | $5,803 |
| Intuitive Surgical | 13 | $1,816 |
| Verity Pharmaceuticals Inc. | 1 | $1,600 |
| Provepharm Inc. | 1 | $1,600 |
| Rochester Medical Corporation | 23 | $229 |
| Seagen Inc. | 2 | $228 |
| C. R. Bard, Inc. & Subsidiaries | 16 | $194 |
| AbbVie | 5 | $166 |
| Genentech, Inc. | 1 | $149 |
| Genentech USA, Inc. | 1 | $149 |
| AVEO Pharmaceuticals, Inc. | 1 | $144 |
| Smith+Nephew | 1 | $144 |
| Astellas Pharma Inc | 1 | $141 |
| Dendreon Pharmaceuticals LLC | 1 | $106 |
| BD | 2 | $27 |
| 180 Medical, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,322,949 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 34 | $37,702 |
| MyrbetriqMirabegron | 15 | $19,999 |
| Tamsulosin Hcl | 113 | $1,559 |
| Finasteride | 52 | $629 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $88 |
| Ciprofloxacin Hcl | 17 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $6,223 | $19,99915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in Los Angeles
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.7M
- Brian ShuchLos Angeles$1.5M
- David JosephsonLos Angeles$1.5M
- Saum GhodoussipourLos Angeles$1.1M
- Stuart HoldenLos Angeles$1.1M
- William AronsonLos Angeles$951K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.